List of Excipients in Branded Drug FOTIVDA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AVEO Pharmaceuticals Inc	FOTIVDA	tivozanib	45629-089	MAGNESIUM STEARATE	2028-11-16
AVEO Pharmaceuticals Inc	FOTIVDA	tivozanib	45629-089	MANNITOL	2028-11-16

Fotivda Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Fotivda, the oral tivozanib product marketed by Aveo Oncology, uses a relatively simple hard-gelatin capsule platform with mannitol, magnesium stearate, sodium lauryl sulfate, and capsule-shell colorants. The formulation creates opportunities in excipient supply, low-dose content uniformity, capsule-shell technology, stability enhancement, generic development, and lifecycle reformulation. The largest commercial opportunity is likely a compliant, ready-to-use excipient system that improves blend uniformity and manufacturing robustness without changing the immediate-release profile.

What is Fotivda and how is it formulated?

Fotivda contains tivozanib hydrochloride monohydrate and is approved in the United States for adults with relapsed or refractory advanced renal cell carcinoma after at least two prior systemic therapies [1].

The product is available in two strengths:

Product	Tivozanib strength	Dosage form	Administration
Fotivda	0.89 mg	Hard capsule	One capsule once daily for 21 days, followed by 7 days off
Fotivda	1.34 mg	Hard capsule	One capsule once daily for 21 days, followed by 7 days off

The recommended regimen creates a 28-day treatment cycle. Patients continue treatment until disease progression or unacceptable toxicity [1].

The US prescribing information identifies the following inactive ingredients:

Formulation component	Function
Mannitol	Diluent and bulking agent
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting or surfactant component
Gelatin	Capsule shell
Titanium dioxide	Opacifier and colorant
Iron oxide and/or FD&C Blue No. 2 colorants	Strength identification and product appearance

The public prescribing information does not disclose quantitative excipient levels. That limits direct replication of the commercial formulation from label information alone.

What excipient strategy does Fotivda use?

Fotivda uses a conventional solid oral dosage platform rather than a complex modified-release, lipid-based, amorphous dispersion, or multiparticulate system. The strategy appears designed to support:

1. Low-dose active-ingredient distribution.
2. Rapid and reproducible capsule manufacture.
3. Immediate-release drug delivery.
4. Visual differentiation between the 0.89 mg and 1.34 mg strengths.
5. A capsule product that can be administered with or without food.

Mannitol provides bulk in a formulation containing less than 1.5 mg of active ingredient per capsule. At this dose, content uniformity is a central manufacturing issue. The active ingredient must be distributed consistently through the powder blend despite its low concentration.

Sodium lauryl sulfate can improve wetting and dissolution of a poorly water-soluble active pharmaceutical ingredient. Magnesium stearate supports capsule-filling operations by reducing friction and adhesion, but excessive lubrication can reduce powder wettability or slow dissolution. The formulation therefore depends on controlled lubricant concentration and blending time.

The hard-gelatin shell provides a low-cost, established delivery platform. The color system allows strength differentiation, reducing dispensing and administration errors in a two-strength oncology regimen.

What commercial opportunities exist for Fotivda excipients?

The strongest opportunities are in formulation components that address low-dose uniformity, dissolution consistency, capsule stability, and manufacturing scale-up.

Ready-to-use low-dose premixes

A supplier could develop a premixed mannitol-surfactant system optimized for low-dose kinase inhibitors. A standardized premix could reduce the number of manufacturing steps and improve homogeneity before addition of tivozanib hydrochloride.

Commercial value would depend on:

• Demonstrated blend uniformity at low drug loading.
• Consistent bulk density and flow.
• Low segregation during transfer and encapsulation.
• Compatibility with magnesium stearate.
• Support for scale-up and process validation.
• Documentation suitable for abbreviated new drug applications.

A supplier would need to avoid creating a formulation that is materially different from the reference product in dissolution, impurity formation, or bioavailability.

Direct-compression and low-shear mannitol grades

Mannitol grades differ in particle size, morphology, flow, and compressibility. Although Fotivda is encapsulated, these properties still affect powder handling and capsule-filling performance.

Potential products include:

• Low-segregation mannitol grades.
• Co-processed mannitol systems with improved flow.
• Granulated mannitol for more consistent active distribution.
• Low-moisture grades for moisture-sensitive kinase inhibitors.

The most defensible commercial position would be a grade supported by comparative dissolution, blend-uniformity, and capsule-filling data rather than a generic claim of superior flow.

Surfactant alternatives

Sodium lauryl sulfate is effective but can create tolerability, taste, regulatory, or supplier-qualification concerns in some markets. Potential alternatives include poloxamers, sodium docusate, or other pharmacopeial surfactants.

A substitution strategy would face a high regulatory burden because the surfactant may influence:

• Wetting.
• Dissolution rate.
• Exposure.
• Food-effect behavior.
• Stability.
• Gastrointestinal tolerability.

A successful alternative would need to match the reference product’s dissolution profile across pH conditions and demonstrate bioequivalence where required.

Capsule-shell technologies

The capsule shell is a practical opportunity for contract manufacturers and excipient suppliers. Relevant products include:

• Gelatin shells with tighter moisture specifications.
• Hypromellose shells for vegetarian or regional market requirements.
• Low-moisture shells.
• Enhanced-color uniformity systems.
• Shells with improved resistance to brittleness and cross-linking.

A hypromellose substitution could expand market access but would not automatically be a generic-equivalent strategy. The shell affects disintegration, moisture transfer, oxygen exposure, mechanical performance, and visual appearance.

Colorant and strength-identification systems

Fotivda uses different capsule appearances for its two strengths. A supplier could offer standardized colorant systems that preserve distinct visual identification while reducing batch-to-batch variation.

The commercial opportunity is strongest in markets with:

• Restrictions on specific synthetic colorants.
• Different permitted iron oxide specifications.
• Requirements for vegetarian capsules.
• Local serialization or packaging rules.
• Patient-safety concerns involving look-alike oncology capsules.

Any color change would require assessment of labeling, product appearance, stability, and regulatory comparability.

What formulation patents protect Fotivda?

The core commercial protection for Fotivda is expected to center on tivozanib composition, therapeutic use, and regulatory exclusivity rather than a publicly prominent excipient platform.

The FDA label identifies tivozanib hydrochloride monohydrate as the active ingredient but does not describe a proprietary controlled-release or complex delivery technology [1]. This makes excipient differentiation more commercially relevant for generic manufacturers and formulation suppliers than for licensing a complex drug-delivery platform.

Patent and Orange Book analysis should distinguish among:

• Composition-of-matter patents covering tivozanib or its salt.
• Method-of-use patents covering renal cell carcinoma treatment.
• Formulation patents covering a particular capsule or excipient combination.
• Process patents covering synthesis, crystallization, or purification.
• Regulatory exclusivity associated with the original approval.

The FDA Orange Book is the controlling public source for patents listed against an approved small-molecule product [2]. The current Orange Book entry should be reviewed for active listings, pediatric extensions, and any patent-use codes before making a generic-entry or freedom-to-operate decision.

When does Fotivda lose exclusivity?

Fotivda does not have biosimilar exclusivity risk because tivozanib is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an abbreviated new drug application, potentially supported by a Paragraph IV certification against listed patents.

US market-entry timing depends on four factors:

Factor	Commercial impact
Orange Book patent expiry	Determines the earliest routine generic-entry date
Paragraph IV litigation	Can trigger a 30-month stay under applicable conditions
Regulatory exclusivity	May delay ANDA approval even after patent issues are resolved
Settlement agreement	May establish an earlier licensed-entry date

A generic applicant could seek approval using the same active ingredient and a different excipient system if the product meets pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. The applicant would not generally need to duplicate every inactive ingredient.

What generic-entry risks exist for Fotivda?

The generic risk is moderate from a formulation standpoint but potentially constrained by patent and market economics.

Technical risks

The principal technical risks are:

• Low-dose content-uniformity failure.
• Powder segregation during capsule filling.
• Dissolution differences caused by surfactant substitution.
• Shell-related disintegration differences.
• Stability changes from moisture or gelatin interaction.
• Inconsistent capsule appearance between strengths.

The low dose makes a conventional formulation possible but increases the importance of process control. A generic manufacturer may prefer a quantitative formulation close to the reference product to reduce bioequivalence risk.

Regulatory risks

FDA approval requires pharmaceutical equivalence and bioequivalence under the ANDA pathway. The product must also meet requirements for identity, strength, quality, purity, stability, and manufacturing controls [3].

If a generic uses a different capsule shell or color system, it must address:

• Inactive-ingredient safety.
• Product appearance.
• Labeling and identification.
• Dissolution comparability.
• Manufacturing and stability data.

Commercial risks

Tivozanib is used in a defined later-line renal cell carcinoma population. That limits total volume relative to mass-market oral oncology products. Generic competition could produce rapid price erosion if multiple manufacturers enter simultaneously.

The small patient population may also reduce the economic incentive to develop multiple differentiated excipient systems. A supplier’s best opportunity may therefore be to support a lead generic manufacturer, contract manufacturer, or regional licensee rather than build a standalone Fotivda-equivalent platform.

Which companies are relevant to Fotivda commercial opportunities?

Aveo Oncology commercializes Fotivda in the United States. Aveo is part of LG Chem Life Sciences, while tivozanib development and commercialization have involved HLB and related entities in different territories [4].

The relevant commercial counterparties include:

• Tivozanib patent holders and licensees.
• Generic pharmaceutical companies developing tivozanib capsules.
• Capsule-shell manufacturers.
• Mannitol and surfactant suppliers.
• Contract development and manufacturing organizations.
• Oncology-focused regional distributors.
• Companies developing renal cell carcinoma combination regimens.

The most attractive partnership model is likely a formulation-support agreement involving excipient qualification, process development, analytical method transfer, and regulatory documentation.

How does Fotivda compare with competing oral renal cell carcinoma drugs?

Fotivda competes with oral targeted therapies including axitinib, cabozantinib, pazopanib, and sunitinib. These products differ in active dose, tablet or capsule presentation, excipient complexity, and lifecycle position.

Product	Active ingredient	Common dosage form	Excipient opportunity
Fotivda	Tivozanib	Hard capsule	Low-dose uniformity, shell technology, surfactant optimization
Inlyta	Axitinib	Tablet	Tablet coating, solid-state control, generic manufacturing
Cabometyx	Cabozantinib	Tablet	Solid dispersion and dissolution control
Votrient	Pazopanib	Tablet	Solubility, tablet coating, food-effect management
Sutent	Sunitinib	Capsule	Capsule shell, low-dose content uniformity, color differentiation

Fotivda’s capsule format may offer more flexibility for shell and fill-material innovation than a film-coated tablet. Its small active dose also makes excipient selection and blending more important than total tablet mass.

What manufacturing and IP barriers affect Fotivda excipient suppliers?

Excipient suppliers face three main barriers.

Qualification barriers

A supplier must demonstrate consistent compendial quality, supply continuity, change-control discipline, and global regulatory acceptability. Oncology products typically require tight impurity, particulate, microbial, and elemental impurity controls.

Process-transfer barriers

A new excipient grade can alter the manufacturing process even when the qualitative composition remains unchanged. Relevant variables include:

• Order of addition.
• Blend time.
• Screen size.
• Lubrication time.
• Encapsulation speed.
• Powder hold time.
• Environmental humidity.
• Capsule-shell storage conditions.

Intellectual-property barriers

A supplier may avoid direct infringement of formulation patents by selling a general-purpose excipient grade. That position is weaker if the product is marketed with claims directed specifically to a patented tivozanib formulation or process.

The safer commercial strategy is to sell an excipient or co-processed material with platform-level claims supported by independent technical data. The customer, rather than the supplier, would then determine whether the final product practices a listed or unlisted patent.

What is the FDA regulatory status of Fotivda?

FDA approved Fotivda on March 10, 2021, for adults with relapsed or refractory advanced renal cell carcinoma after at least two prior systemic therapies [1]. The approval was based on clinical evidence including the TIVO-3 study, which evaluated tivozanib against sorafenib in previously treated advanced renal cell carcinoma [5].

Fotivda is an FDA-approved small-molecule prescription drug. It is not subject to the biosimilar pathway. Generic competitors would ordinarily use the ANDA pathway, subject to Orange Book patent certifications and any applicable regulatory exclusivity [2,3].

How strong is the Fotivda excipient strategy?

The formulation is operationally strong but not highly differentiated based on publicly disclosed information.

Its strengths are:

• Simple immediate-release capsule architecture.
• Established excipients.
• Two-strength visual differentiation.
• Low ingredient complexity.
• Compatibility with conventional capsule manufacturing.

Its weaknesses are:

• Low active loading creates content-uniformity sensitivity.
• Surfactant selection can affect dissolution and tolerability.
• Gelatin shells create regional and dietary restrictions.
• Publicly disclosed formulation information does not establish a strong standalone excipient patent position.
• Generic manufacturers can likely pursue alternative inactive ingredients.

The formulation’s commercial defensibility is therefore more likely to come from process know-how, analytical control, supplier qualification, and regulatory execution than from a broad excipient patent moat.

Key Takeaways

• Fotivda is an immediate-release tivozanib hydrochloride monohydrate hard capsule.
• Public labeling identifies mannitol, magnesium stearate, sodium lauryl sulfate, gelatin, titanium dioxide, and capsule colorants.
• The core formulation challenge is uniform distribution of a very low active dose.
• The strongest excipient opportunities are low-segregation mannitol systems, surfactant alternatives, low-moisture capsule shells, and validated colorant platforms.
• Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
• Patent risk must be assessed through the current FDA Orange Book entry and applicable tivozanib composition, use, formulation, and process patents.
• The formulation appears commercially practical but does not present a clearly dominant public excipient patent estate.
• Supplier value will depend on documented blend uniformity, dissolution comparability, stability, and regulatory support.

FAQs

Can Fotivda be reformulated as a tablet?

Yes. A tablet could be developed, but it would require new formulation development, dissolution testing, stability work, and bioequivalence assessment. A tablet would not automatically qualify as pharmaceutically equivalent to the reference capsule.

Which Fotivda excipient is most important for dissolution?

Sodium lauryl sulfate is the most likely dissolution-relevant excipient because it improves wetting. Its level and blending conditions must be controlled because excessive surfactant or over-lubrication can alter release.

Can a generic tivozanib product use different inactive ingredients?

Generally, yes, provided the product meets applicable FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and labeling. The alternative excipients must not create clinically meaningful differences.

Is a vegetarian version of Fotivda commercially feasible?

A hypromellose capsule could provide a vegetarian alternative. The manufacturer would need to confirm equivalent disintegration, dissolution, moisture behavior, stability, appearance, and regulatory acceptability.

Does Fotivda have biosimilar competition?

No. Tivozanib is a chemically synthesized small molecule. Competitive products would be generics submitted through the ANDA pathway rather than biosimilars submitted under the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2021). Fotivda (tivozanib) capsules prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2014). ANDA submissions: Content, format, and labeling.
4. Aveo Oncology. (2024). Corporate and product information for Fotivda.
5. Motzer, R. J., et al. (2020). Tivozanib versus sorafenib as third- or fourth-line therapy for metastatic renal cell carcinoma. The Lancet Oncology, 21(1), 95-104.